Expression of PlGF splice variants was not correlated with clinical variables. Interestingly, expression levels of VEGFR-1 predict presence of DTCs in bone marrow (p = 0.002). Patients with DTC in ...

PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clinical Cancer Research, 2016; DOI: 10.1158/1078-0432.CCR-15-1839 ...

In order to wisely skirt this catastrophic event, Lois E. H. Smith and colleagues utilized placental growth factor-1 (PlGF-1), which exclusively activates the VEGF receptor-1 (VEGFR-1).

They also found that targeting the PlGF/VEGFR-1 interaction prevents weight gain in a genetically obese mouse model but worsens a diabetes-like condition, a worsening that was alleviated by use of ...

1. Incio J, Tam J, Rahbari NN, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity [published online February 9, 2016].

VEGFR-1 also serves as a receptor for both PlGF and VEGF-B (ref. 12). Experiments on VEGFR-1 have provided tantalizing data, but have revealed little about its function in adult mice.

Their findings in cellular and animal models, as well as in patient tumor samples, indicate that targeting the PlGF/ VEGFR-1 pathway may be particularly effective in obese patients.

PLGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability.

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the ...

Case Studies > Oncology/Hematology Case: VEGFR Inhibition in Merkel Cell Carcinoma Patient — Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer by ...

More information: J. Incio et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity, Clinical Cancer Research (2016).